Moderna, Inc. (MRNA) debt
What Moderna owes, when it comes due, and what it costs to carry, from the balances and cash flows the company reports to the U.S. Securities and Exchange Commission.
At a glance
| Metric | Jun 2026 | Year earlier | Change |
|---|---|---|---|
| Total debt | $591M | — | — |
| Long-term debt | $591M | — | — |
| Cash and equivalents | $1.72B | — | — |
| Net cash | $1.13B | — | — |
Total debt is the sum of the debt lines the company reports at that date (long-term, current and short-term borrowings), not a figure the company reports as a total.
Debt over time
| Balance date | Total debt | Long-term debt | Cash |
|---|---|---|---|
| Jun 2026 | $591M† | $591M | $1.72B |
| Mar 2026 | $590M† | $590M | $1.91B |
| Dec 2025 | $590M† | $590M | $2.60B |
| Dec 2024 | $0† | $0 | $1.93B |
† Sum of the debt lines the company reports at that date, not a reported total.
About these figures
These are the balances Moderna reports in its SEC filings as of each balance-sheet date, and the interest, borrowing and repayments it reports for each period. This page does not show market prices or yields of the company's bonds. "Long-term debt" is the line as the company tags it in its filings and may or may not include the portion due within a year.
All figures from company filings with the SEC.